Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma

  1. Simone Hettmer
  2. Anna C Schinzel
  3. Daria Tchessalova
  4. Michaela Schneider
  5. Christina L. Parker
  6. Roderick Bronson
  7. Nigel G.J. Richards
  8. William Hahn
  9. Amy J Wagers  Is a corresponding author
  1. University Medical Center Freiburg, Germany
  2. Dana-Farber Cancer Institute, United States
  3. University of Michigan, United States
  4. University of North Carolina, United States
  5. Harvard University, United States
  6. Indiana University - Purdue University Indianapolis, United States
  7. Dana Farber Cancer Institute, United States

Abstract

Current therapies for sarcomas are often inadequate. This study sought to identify actionable gene targets by selective targeting of the molecular networks that support sarcoma cell proliferation. Silencing of asparagine synthetase (ASNS), an amidotransferase that converts aspartate into asparagine, produced the strongest inhibitory effect on sarcoma growth in a functional genomic screen of mouse sarcomas generated by oncogenic Kras and Cdkn2a. ASNS silencing in mouse and human sarcoma cell lines reduced the percentage of S phase cells and impeded new polypeptide synthesis. These effects of ASNS silencing were reversed by exogenous supplementation with asparagine. Also, asparagine depletion via the ASNS inhibitor amino sulfoximine 5 (AS5) or asparaginase inhibited mouse and human sarcoma growth in vitro, and genetic silencing of ASNS in mouse sarcoma cells combined with depletion of plasma asparagine inhibited tumor growth in vivo. Asparagine reliance of sarcoma cells may represent a metabolic vulnerability with potential anti-sarcoma therapeutic value.

Article and author information

Author details

  1. Simone Hettmer

    Pediatric Hematology/ Oncology, University Medical Center Freiburg, Freiburg, Germany
    Competing interests
    No competing interests declared.
  2. Anna C Schinzel

    Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  3. Daria Tchessalova

    Neuroscience Graduate Program, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  4. Michaela Schneider

    Pediatric hematology/ oncology, University Medical Center Freiburg, Freiburg, Germany
    Competing interests
    No competing interests declared.
  5. Christina L. Parker

    Molecular Pharmaceutics, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  6. Roderick Bronson

    Harvard Medical School, Harvard University, Boston, United States
    Competing interests
    No competing interests declared.
  7. Nigel G.J. Richards

    Chemistry & Chemical Biology, Indiana University - Purdue University Indianapolis, Indianapolis, United States
    Competing interests
    No competing interests declared.
  8. William Hahn

    Dana Farber Cancer Institute, *, United States
    Competing interests
    No competing interests declared.
  9. Amy J Wagers

    Harvard Stem Cell Institute, Harvard University, United States
    For correspondence
    amy.wagers@joslin.harvard.edu
    Competing interests
    Amy J Wagers, Reviewing editor, eLife.

Reviewing Editor

  1. Hideyuki Okano, Keio University School of Medicine, Japan

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Joslin Diabetes Center. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Joslin Diabetes Center. All surgery was performed under tribromoethanol or isoflurane anesthesia, and every effort was made to minimize suffering.

Version history

  1. Received: June 15, 2015
  2. Accepted: October 23, 2015
  3. Accepted Manuscript published: October 24, 2015 (version 1)
  4. Version of Record published: December 17, 2015 (version 2)

Copyright

© 2015, Hettmer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,672
    views
  • 622
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Simone Hettmer
  2. Anna C Schinzel
  3. Daria Tchessalova
  4. Michaela Schneider
  5. Christina L. Parker
  6. Roderick Bronson
  7. Nigel G.J. Richards
  8. William Hahn
  9. Amy J Wagers
(2015)
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma
eLife 4:e09436.
https://doi.org/10.7554/eLife.09436

Share this article

https://doi.org/10.7554/eLife.09436

Further reading

    1. Cancer Biology
    2. Cell Biology
    Timothy J Walker, Eduardo Reyes-Alvarez ... Lois M Mulligan
    Research Article

    Internalization from the cell membrane and endosomal trafficking of receptor tyrosine kinases (RTKs) are important regulators of signaling in normal cells that can frequently be disrupted in cancer. The adrenal tumor pheochromocytoma (PCC) can be caused by activating mutations of the rearranged during transfection (RET) receptor tyrosine kinase, or inactivation of TMEM127, a transmembrane tumor suppressor implicated in trafficking of endosomal cargos. However, the role of aberrant receptor trafficking in PCC is not well understood. Here, we show that loss of TMEM127 causes wildtype RET protein accumulation on the cell surface, where increased receptor density facilitates constitutive ligand-independent activity and downstream signaling, driving cell proliferation. Loss of TMEM127 altered normal cell membrane organization and recruitment and stabilization of membrane protein complexes, impaired assembly, and maturation of clathrin-coated pits, and reduced internalization and degradation of cell surface RET. In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.

    1. Cancer Biology
    2. Cell Biology
    Julian JA Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article Updated

    Collective cell migration is fundamental for the development of organisms and in the adult for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell–cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell–cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell–cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective SC migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased SC collective migration and increased clustering of SCs within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.